Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-05-23
2006-05-23
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S085100, C514S049000, C514S050000, C514S252100, C514S255010, C514S256000, C514S934000
Reexamination Certificate
active
07048924
ABSTRACT:
Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing regimen in combination with administration of a pharmaceutical composition comprising a therapeutically effective amount of interleukin-2 (IL-2) or variant thereof. The combination of daily or intermittent administration of IL-2 (or variant thereof) and intermittent HAART promotes immunologic control of viral replication in the absence of HAART, thereby prolonging the length of time a patient may discontinue HAART before viral rebound necessitates further administration of HAART. Administration of IL-2 therapy in combination with an intermittent HAART dosing regimen provides an effective method for treating a subject infected with HIV.
REFERENCES:
patent: 5419900 (1995-05-01), Lane et al.
patent: 5969079 (1999-10-01), Lubowitz et al.
patent: 2002/0048584 (2002-04-01), Pomerantz
patent: WO 99/26658 (1999-06-01), None
patent: WO 99/48526 (1999-09-01), None
Gallant “A review of dual protease inhibitor therapy”, Hopkins HIV report: a bimonthly newsletter for healthcare providers, Johns Hopkins University AIDS Service, 10(3) (May 1998), pp. 4-5.
Riffkin et al. A single amino-acid change between the antigenically different extracellular serine protease V2 and B2 from Dichelobacter nodous. Gene (1995) vol. 167, pp. 279-283.
Ngo et al, in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Edited by Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Beal, L.J., et al., “Low-Dose Subcutaneous (SC) in Combination with HAART Therapy Induces Significant Increases in NK Cells and Naive T-Cells in Patients with <300 CD4: T-Cells/mm3: Results of a Randomized Controlled Trial MA-9801.”Conf Retroviruses Opportunistic Infect. 2000, 7:148.
Chun, T., et al., “Effect of Interleukin-2 on the Pool of Latently Infected, Resting CD4+ Cells in HIV-1 Infected Patients Receiving Highly Active Anti-Retroviral Therapy,”Nature Medicine, 1999, pp. 651-655, vol. 5(6).
Alvarado-Diez, R., et al., “Interleukin 2 Plus HAART Does Not Increase the Viral load,”XIII International AIDS Conference, 2000, Abstract No. WePeA4086.
Arendt, P., et al., IL-2 in Patients with Low CD4 and Resistant Virus: Efficacy and Cytokine (CK)/Chemokine (ChK) Profiles,XIII International AIDS Conference, 2000, Abstract No. ThPeB5033.
Arno, et al., “Efficacy of Low-Dose Subcutaneous Interleukin-2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with </=250/microl. CD4 T Cells and Undetectable Plasma Virus Load,”Journal of Infectious Diseases, 1999, pp. 56-60, vol. 180(1).
Carpenter, C., et al., “Antiretroviral Therapy in Adults,”JAMA, 2000, pp. 381-391, vol. 283(3).
Davey, P., et al., “HIV-I and T Cell Dynamics After Interruption of Highly Active Antiretroviral Therapy (HAART) in Patients with a History of Sustained Viral Suppression,”PNAS, 1999, pp. 15109-15114, vol. 96(26).
Emert, R., et al., “Structured Antiviral Treatment Interruption Followed by Daily Low Dose Interleukin 2 (I1-2) Revea's Immune Response to HIV,”XIII International AIDS Conference, 2000, Abstract No. WePeB4285.
Fisher, M., et al., “Randomised Study of Intermittent Subcutaneous Interleukin-2 (IL-2) Therapy Without Anti-Retrovirals Versus No Treament,”XIII International AIDS Conference, 2000, Abstract No. LbOr28.
Hecht, F., et al., “A Randomized Trial of IL-2 Added to HAART for Primary IIIV Infection,”XIII International AIDS Conference, 2000, Abstract No. WeOrB541.
Hengge, et al., “Randomized, Controlled Phase II Trial of Subcutaneous Interleukin-2 in combination with Highly Active Antiretroviral Therapy (HAART) in HIV Patients,”AIDS, 1998, pp. 1225-1234, vol. 12(17).
Levy, Y., et al., “Long Term (3 Years) Efficacy of IL2 Therapy in HIV-Infected Patients. Results of the Follow-up of the Randomized ANRS 048 Trial,”XIII International AIDS Conference, 2000, Abstract No. ThPeB5032.
Malnati, M., et al., “Retrospective Analysis of HHV-8 Plasma Viremia and Cellular Viral Load in a Cohort of HIV-Seropositive Individuals Receiving HAART—IL-2,”XIII International AIDS Conference, 2000, Abstract No. WePeA4009.
Oliva, A., et al., “Effects ofIn VivoIL-2 Administration onIn VitroCC-Chemokine Production and Viral Isolation in HIV-Infected Individuals Receiving HAART,”XIII International AIDS Conference, 2000, Abstract No. WeOrB490.
Ostrowski, M., et al., “The Role of CD4+T Cell Help and CD40 Ligand in the Expanison of HIV-Specific Memory Cytotoxic CD8+T Cell Responses.”XIII International AIDS Conference, 2000, Abstract No. TuPeA3040.
Pahwa, et al., “Interleukin-2 Therapy in HIV Infection,”AIDS Patient Care and STDS, 1998, pp. 187-197, vol. 12(3).
Ruiz, L., et al., “Structured Treatment Interruption in Chronically HIV-1 Infected Patients After Long-Term Suppression,”AIDS, 2000, pp. 397-403, vol. 14(4).
Ruxrungtham, K., “Naive and Memory Phenotypes of CD4+T Cells and mRNA Expression of IL-2 in HIV-Infected Thai patients Treated with Various Doses of Subeutaneous (SC) IL-2,”XIII International AIDS Conference, 2000, Abstract No. ThPpB1481.
Umscheid, C., et al., “HIV Envelope Induces Virus Expression in the HIV-Infected Resting CD4+T Cell Reservoir without Inducing Cellular Activation or Apoptosis,”XIII International AIDS Conference, 2000, Abstract LbPeA7024.
Wodarz, et al., “Specific Therapy Regimes Could Lead to Long-Term Immunological Control of HIV,”Proceedings of the National Academy of Sciences, 1999, pp. 14464-14469, vol. 96(25).
Yoder, C., et al., A Randomized Controlled Trial of Intermittent Versus Continuous Highly Active Antiretroviral Therapy (HAART),XIII International AIDS Conference, 2000, Abstract No. LbOr11.
Yoder, C., et al., “Short Cycle Intermittent HAART: A Pilot Study,”XIII International AIDS Conference, 2000, Abstract No. LbOr12.
Chiron Corporation
Harbin Alisa A.
Hessler Amy L.
Robins Roberta L.
Stucker Jeffrey
LandOfFree
Combination antiviral and interleukin-2 therapy for HIV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination antiviral and interleukin-2 therapy for HIV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination antiviral and interleukin-2 therapy for HIV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582237